BTIG downgraded Vericel (VCEL) to Neutral from Buy without a price target The stock is down 42% this year following two “softer” quarters, the analyst tells investors in a research note. BTIG’s survey of MACI users suggests limited increases in both biopsy growth and conversion from the MACI Arthro launch to drive estimates higher. The firm points out that 60% of surgeons surveyed expect no change to MACI volumes despite Arthro as an option now.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCEL:
- Vericel’s Phase 3 Study on MACI: A Potential Game-Changer in Cartilage Repair
- Vericel’s MACI Arthro: Driving Over 20% Growth with Market Expansion and Innovation
- Vericel’s Growth Potential and Attractive Valuation Justify Buy Rating Despite 2Q25 Sales Miss
- Vericel Corporation Reports Strong Q2 2025 Earnings
- Vericel price target lowered to $58 from $61 at Canaccord